Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Cancer Invest
; 32(4): 150-7, 2014 May.
Article
in En
| MEDLINE
| ID: mdl-24605899
ABSTRACT
INTRODUCTION:
We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients.METHODS:
Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage.RESULTS:
There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin.CONCLUSION:
Despite no proliferation changes, we observed reductions in other relevant biomarkers.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Cell Proliferation
/
Overweight
/
Metformin
/
Antineoplastic Agents
/
Obesity
Type of study:
Clinical_trials
/
Diagnostic_studies
Limits:
Aged
/
Female
/
Humans
/
Middle aged
Country/Region as subject:
America do norte
Language:
En
Journal:
Cancer Invest
Year:
2014
Document type:
Article
Affiliation country:
United States